• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Eikon Therapeutics Inc.

    2/18/26 4:16:58 PM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $EIKN alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Eikon Therapeutics, Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    282564103

    (CUSIP Number)


    02/04/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    282564103


    1Names of Reporting Persons

    Abu Dhabi Investment Authority
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED ARAB EMIRATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    1,669,576.00
    6Shared Voting Power

    1,147,138.00
    7Sole Dispositive Power

    1,669,576.00
    8Shared Dispositive Power

    1,147,138.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,816,714.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.2 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  (1) Abu Dhabi Investment Authority is the direct owner of 1,669,576 of the shares of Common Stock represented herein. (2) The percent calculation is based on 53,984,337 shares of Common Stock outstanding, after giving effect to the completion of the offering as described in Eikon Therapeutics, Inc.'s prospectus filed pursuant to Rule 424(b)(4) with the Securities and Exchange Commission on February 5, 2026.


    SCHEDULE 13G

    CUSIP No.
    282564103


    1Names of Reporting Persons

    Platinum Falcon B 2018 RSC Limited
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED ARAB EMIRATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,147,138.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,147,138.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,147,138.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    2.1 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  (1) Platinum Falcon B 2018 RSC Limited ("Platinum Falcon") is the direct owner of 1,147,138 of the shares of Common Stock reported herein. Platinum Falcon is a wholly owned subsidiary of Abu Dhabi Investment Authority. Pursuant to the rules and regulations of the Securities and Exchange Commission, Abu Dhabi Investment Authority may be deemed to be the beneficial owner of the shares of Common Stock directly held by Platinum Falcon. (2) The percent calculation based on 53,984,337 shares of Common Stock outstanding after giving effect to the completion of the offering as described in Eikon Therapeutics, Inc.'s prospectus filed pursuant to Rule 424(b)(4) with the Securities and Exchange Commission on February 5, 2026.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Eikon Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    230 Harriet Tubman Way, Millbrae CA 94030
    Item 2. 
    (a)Name of person filing:

    This Schedule 13G is being filed on behalf of the following: 1. Abu Dhabi Investment Authority 2. Platinum Falcon B 2018 RSC Limited
    (b)Address or principal business office or, if none, residence:

    The principal business address of each of the Reporting Persons is as follows: 1. 211 Corniche Street P.O. Box 3600 Abu Dhabi, United Arab Emirates 3600 2. Level 26, Al Khatem Tower Abu Dhabi Global Market Square Al Maryah Island, Abu Dhabi United Arab Emirates
    (c)Citizenship:

    1. Abu Dhabi Investment Authority (ADIA) is a public institution established by the Government of the Emirate of Abu Dhabi in 1976 as an independent investment institution. ADIA is a public institution. 2. Platinum Falcon B 2018 RSC Limited is a restricted scope company organized under the laws of the Abu Dhabi Global Market, Abu Dhabi, United Arab Emirates.
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    282564103
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See responses to Item 9 on each cover page.
    (b)Percent of class:

    See responses to Item 11 on each cover page.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See responses to Item 5 on each cover page.

     (ii) Shared power to vote or to direct the vote:

    See responses to Item 6 on each cover page.

     (iii) Sole power to dispose or to direct the disposition of:

    See responses to Item 7 on each cover page.

     (iv) Shared power to dispose or to direct the disposition of:

    See responses to Item 8 on each cover page.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Abu Dhabi Investment Authority
     
    Signature:/s/ Saif Surour Omair Maaded AlMashghouni
    Name/Title:Authorized Signatory
    Date:02/18/2026
     
    Signature:/s/ Ahmed Salem Abdulla Melaih AlNeyadi
    Name/Title:Authorized Signatory
    Date:02/18/2026
     
    Platinum Falcon B 2018 RSC Limited
     
    Signature:/s/ Saif Surour Omair Maaded AlMashghouni
    Name/Title:Authorized Signatory
    Date:02/18/2026
     
    Signature:/s/ Ahmed Salem Abdulla Melaih AlNeyadi
    Name/Title:Authorized Signatory
    Date:02/18/2026
    Exhibit Information

    Exhibit 1: Joint Filing Agreement

    Get the next $EIKN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EIKN

    DatePrice TargetRatingAnalyst
    3/2/2026Overweight
    Cantor Fitzgerald
    3/2/2026$32.00Overweight
    Morgan Stanley
    3/2/2026$29.00Overweight
    Analyst
    3/2/2026$26.00Outperform
    Mizuho
    3/2/2026$34.00Buy
    BofA Securities
    2/26/2026$7.00Underperform
    Wedbush
    More analyst ratings

    $EIKN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Column Group Iv Gp, Lp converted options into 3,595,340 shares and bought $38,119,680 worth of shares (2,117,760 units at $18.00) (SEC Form 4)

    4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)

    2/9/26 9:19:00 PM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Foresite Capital Management Iv, Llc converted options into 4,041,687 shares and bought $999,990 worth of shares (55,555 units at $18.00) (SEC Form 4)

    4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)

    2/6/26 7:37:49 PM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Frazier Kenneth C bought $1,999,998 worth of shares (111,111 units at $18.00) (SEC Form 4)

    4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)

    2/6/26 6:33:01 PM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EIKN
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Eikon Therapeutics Inc.

    SCHEDULE 13G - Eikon Therapeutics, Inc. (0001861123) (Subject)

    2/18/26 4:16:58 PM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13D filed by Eikon Therapeutics Inc.

    SCHEDULE 13D - Eikon Therapeutics, Inc. (0001861123) (Subject)

    2/12/26 6:48:54 PM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13G filed by Eikon Therapeutics Inc.

    SCHEDULE 13G - Eikon Therapeutics, Inc. (0001861123) (Subject)

    2/11/26 4:08:44 PM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EIKN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Operating Officer Klobuchar Michael A

    4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)

    3/4/26 5:04:29 PM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Huffines Robert Luther

    4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)

    3/4/26 5:02:00 PM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Frazier Kenneth C

    4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)

    3/4/26 5:01:49 PM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EIKN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Eikon Therapeutics

    Cantor Fitzgerald initiated coverage of Eikon Therapeutics with a rating of Overweight

    3/2/26 9:11:04 AM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Morgan Stanley initiated coverage on Eikon Therapeutics with a new price target

    Morgan Stanley initiated coverage of Eikon Therapeutics with a rating of Overweight and set a new price target of $32.00

    3/2/26 9:06:14 AM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Analyst initiated coverage on Eikon Therapeutics with a new price target

    Analyst initiated coverage of Eikon Therapeutics with a rating of Overweight and set a new price target of $29.00

    3/2/26 9:05:58 AM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care